Dobrek Lukasz
Department of Clinical Pharmacology, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Pharmaceutics. 2021 Nov 12;13(11):1915. doi: 10.3390/pharmaceutics13111915.
The objective of the optimization of pharmacotherapy compliant with the basic rules of clinical pharmacology is its maximum individualization, ensuring paramount effectiveness and security of the patient's therapy. Thus, multiple factors that are decisive in terms of uniqueness of treatment of the given patient must be taken into consideration, including, but not limited to, the patient's age, sex, concomitant diseases, special physiological conditions (e.g., pregnancy, lactation, extreme age groups), polypharmacotherapy and polypragmasia (particularly related to increased risk of drug interactions), and patient's phenotypic response to the administered drug with possible genotyping. Conducting therapy while monitoring the concentration of certain drugs in blood (Therapeutic Drug Monitoring; TDM procedure) is also one of the factors enabling treatment individualization. Furthermore, another material, and yet still a marginalized pharmacotherapeutic factor, is chronopharmacology, which indirectly determines the values of drug concentrations evaluated in the TDM procedure. This paper is a brief overview of chronopharmacology, especially chronopharmacokinetics, and its connection with the clinical interpretation of the meaning of the drug concentrations determined in the TDM procedure.
符合临床药理学基本规则的药物治疗优化目标是实现最大程度的个体化,确保患者治疗的最高有效性和安全性。因此,必须考虑多个对特定患者治疗独特性起决定性作用的因素,包括但不限于患者的年龄、性别、伴发疾病、特殊生理状况(如妊娠、哺乳期、极端年龄组)、多药治疗和多药并用(尤其与药物相互作用风险增加有关),以及患者对所给药的表型反应及可能的基因分型。在监测血液中某些药物浓度的同时进行治疗(治疗药物监测;TDM程序)也是实现治疗个体化的因素之一。此外,时间药理学是另一个重要但仍被边缘化的药物治疗因素,它间接决定了TDM程序中评估的药物浓度值。本文简要概述时间药理学,尤其是时间药代动力学,及其与TDM程序中所测定药物浓度临床意义解释的关联。